MedTrace Logo

Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis

NCT04088721 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-09-16

No results posted yet for this study

Summary

A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.

Conditions

  • Allergic Rhinitis

Interventions

BIOLOGICAL

AD17002

LTh(αK) as immunomodulator

OTHER

Formulation Buffer

Formulation buffer

Sponsors & Collaborators

  • Clinipace Worldwide

    collaborator INDUSTRY

  • Taipei Medical University

    collaborator OTHER

  • Advagene Biopharma Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Hanpin Kuo · Taipei Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-26
Primary Completion
2020-07-30
Completion
2020-12-11

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088721 on ClinicalTrials.gov